Compass Therapeutics, Inc. CMPX 深 滬
等待開盤 12-20 09:30:00 美东时间
5.16
+0.120
+2.38%
華盛通- 最 高5.19
- 今 開5.07
- 成交量 47.98万股
- 最 低 5.00
- 昨 收 5.04
- 總市值 9.18亿
- 52周最高 5.86
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 1.33
- 委 比 33.27%
- 總股本 1.78亿
- 歷史最高 5.86
- 量 比 0.67
- 振 幅 3.77%
- 歷史最低 0.765
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. The presentation will be available via webcast at cmpx.info/jpmorgan and archived on the company’s Events page. Investors can schedule one-on-one meetings with Compass through their J.P. Morgan or LifeSci Partners representatives during the conference. The company, founded in 2014 and h...
12-17 12:30
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Canaccord Genuity Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $10
Canaccord Genuity analyst John Newman initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Buy rating and announces Price Target of $10.
12-03 20:35
Compass Therapeutics to Participate in Upcoming December Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology, announced its participation in two investor events in December. The events include the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the 8th Annual Evercore Healthcare Conference on December 4, 2025. Presentations will be archived for 90 days on Compass’ Events page. Management will be availab...
11-25 13:00
Compass Therapeutics Q3 EPS $(0.08) Beats $(0.14) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.14) by 43.66 percent. This is unchanged from the same period last year.
11-05 20:34
Compass Therapeutics to Participate in Upcoming November Investor Events
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in three investor events in November: the Guggenheim Healthcare Innovation Conference in Boston on November 10, the Stifel Healthcare Conference in New York on November 12, and the Jefferies Global Healthcare Conference in London on November 20. The company develops antibody-based therapies targeting multiple diseases, particularly cance...
11-03 13:00
Comstock Completes Acquisition of Haywood Quarry
Comstock Inc. announced the completion of its $2.2 million purchase of the Haywood quarry industrial and mineral properties in Nevada. The 190-acre property, strategically located near the Company’s existing mineral resources, including the Dayton gold and silver resource, offers power, water, and access to US 50. Comstock's Executive Chairman, Mr. Corrado De Gasperis, emphasized the acquisition's importance in supporting mining operations and pr...
10-15 20:15
Compass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for treating multiple human diseases, will participate in four investor events in September 2025. These include Citi’s Biopharma Back to School Conference in Boston on September 2, the Cantor Global Healthcare Conference in New York on September 3, H.C. Wainwright’s Global Investment Conference in New York on September 8, and Morgan Sta...
08-26 12:00
Compass Therapeutics dips 5%, prices $120M stock
Compass Therapeutics (NASDAQ:CMPX) priced an underwritten public offering of 33.29M shares at $3.00 per share and pre-funded warrants to purchase up to 6.67M shares. The gross proceeds are expected ...
08-13 13:48
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Compass Therapeutics宣布公开发行3329万股普通股，每股定价3美元，同时发行671万股预存股票期权，每股2.9999美元，预计筹资约1.2亿美元，用于商业准备、研究与临床开发及一般公司用途。
08-13 02:28
